Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Whitehawk Therapeutics, Inc. reported an updated large-shareholder position by OrbiMed entities. OrbiMed Advisors LLC and OrbiMed Genesis GP LLC each report beneficial ownership of 3,934,296 shares of Whitehawk Therapeutics common stock, representing 7.3% of the outstanding class as of June 30, 2026.
The OrbiMed entities report no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over 3,934,296 shares. The holdings are maintained on behalf of other persons who have the right to receive dividends or sale proceeds, while OrbiMed Advisors LLC exercises investment and voting power through a management committee whose members disclaim beneficial ownership.
Key Figures
Shares beneficially owned:3,934,296 sharesPercent of class:7.3%Shared voting power:3,934,296 shares+3 more
6 metrics
Shares beneficially owned3,934,296 sharesBeneficial ownership reported by each OrbiMed entity in Whitehawk Therapeutics common stock
Percent of class7.3%Portion of Whitehawk Therapeutics common stock held by OrbiMed entities
Shared voting power3,934,296 sharesShares over which OrbiMed entities have shared power to vote or direct the vote
Shared dispositive power3,934,296 sharesShares over which OrbiMed entities have shared power to dispose or direct disposition
Sole voting power0 sharesShares with sole power to vote or direct the vote by OrbiMed entities
Sole dispositive power0 sharesShares with sole power to dispose or direct disposition by OrbiMed entities
Key Terms
beneficial ownership, shared voting power, shared dispositive power, percent of class, +1 more
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"6 | Shared Voting Power 3,934,296.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"8 | Shared Dispositive Power 3,934,296.00"
percent of classfinancial
"(b) | Percent of class: OrbiMed Advisors LLC: 7.3%"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Investment Company Act of 1940regulatory
"A listing of the shareholders of an investment company registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many WHWK shares do OrbiMed entities beneficially own?
OrbiMed Advisors LLC and OrbiMed Genesis GP LLC each report beneficial ownership of 3,934,296 shares of Whitehawk Therapeutics common stock, reflecting their aggregate position in the company.
What percentage of Whitehawk Therapeutics (WHWK) does OrbiMed own?
The OrbiMed entities together report holding 7.3% of Whitehawk Therapeutics’ common stock, making them significant beneficial owners above the 5% disclosure threshold.
Does OrbiMed have sole or shared voting power over WHWK shares?
OrbiMed reports 0 shares with sole voting power and 3,934,296 shares with shared voting power, indicating voting authority is exercised jointly rather than individually.
Who ultimately benefits from OrbiMed’s WHWK holdings?
The filing states the OrbiMed entities hold 7.3% of WHWK on behalf of other persons who have rights to receive dividends or proceeds from the sale of these securities.
Who exercises investment and voting power for OrbiMed’s WHWK stake?
The document explains that OrbiMed Advisors LLC exercises investment and voting power through a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each disclaiming beneficial ownership.
Is this OrbiMed disclosure for WHWK an amendment?
Yes. The document is identified as Amendment No. 1, updating a prior beneficial ownership report for Whitehawk Therapeutics’ common stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Whitehawk Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
00032Q104
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
OrbiMed Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,934,296.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,934,296.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,934,296.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
OrbiMed Genesis GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,934,296.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,934,296.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,934,296.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Whitehawk Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
2 Headquarters Plaza, East Building, 11th Floor Morristown, New Jersey 07960
Item 2.
(a)
Name of person filing:
OrbiMed Advisors LLC
OrbiMed Genesis GP LLC
(b)
Address or principal business office or, if none, residence:
601 Lexington Avenue, 54th Floor
New York, NY 10022
(c)
Citizenship:
Please refer to Item 4 on each cover sheet for each filing person.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
00032Q104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
OrbiMed Advisors LLC: 3,934,296
OrbiMed Genesis GP LLC: 3,934,296
(b)
Percent of class:
OrbiMed Advisors LLC: 7.3%
OrbiMed Genesis GP LLC: 7.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
OrbiMed Advisors LLC: 0
OrbiMed Genesis GP LLC: 0
(ii) Shared power to vote or to direct the vote:
OrbiMed Advisors LLC: 3,934,296
OrbiMed Genesis GP LLC: 3,934,296
(iii) Sole power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 0
OrbiMed Genesis GP LLC: 0
(iv) Shared power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 3,934,296
OrbiMed Genesis GP LLC: 3,934,296
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Reporting Persons hold 7.3% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
